Fibroblast Growth Factor-1 Induced Promatrilysin Expression Through the Activation of Extracellular-regulated Kinases and STAT3  by Udayakumar, Thirupandiyur S. et al.
Fibroblast Growth Factor-1 Induced Promatrilysin Expression
Through the Activation of Extracellular-regulated Kinases and
STAT3
Thirupandiyur S. Udayakumar*, Mimi Suzanne Stratton*, Raymond B. Nagle y and George Timothy Bowden*
Departments of *Radiation Oncology, yPathology, University of Arizona Health Sciences Center, Tucson,
AZ 85724, USA
Abstract
The MMP, matrilysin (MMP-7), has been shown to be
overexpressed in prostate cancer cells and to increase
prostate cancer cell invasion. Prostate stromal fibro-
blasts secrete factor(s), including fibroblast growth
factor-1 (FGF-1) that induces promatrilysin expression
in LNCaP cells. In the present study, we investigated the
signal transduction pathway involved in the FGF-1–
induced expression of promatrilysin. FGF-1 treatment
significantly increased the activation of extracellular
signal -regulated kinases 1 and 2 (ERK1 and ERK2).
This induction was time-dependent and was sustained
until 24 hours after treatment. Treating the cells with
MEK1/2 inhibitor (PD98059) eliminated ERK activation
completely and blocked FGF-1–mediated induction of
promatrilysin expression. Transient transfection stud-
ies with humanmatrilysin promoter resulted in a four- to
five-fold increase in reporter luciferase enzyme activity
that was blocked by the MEK1/2 inhibitor (PD98059).
Serine phosphorylation of signal transducer and acti-
vator of transcription 3 (STAT3) was observed after
FGF-1 treatment and pretreatment with 20 M PD98059-
abolished STAT3 phosphorylation. Transient transfec-
tion with dominant negative STAT3 inhibited FGF-1–
induced transactivation of the matrilysin promoter
indicating that STAT3 plays an important role in FGF-
1–induced matrilysin expression. We propose that the
FGF-1–induced signaling pathway that leads to proma-
trilysin expression is ERK-dependent and leads to
phosphorylation of Ser-727 on STAT3, phosphorylated
STAT3, then binds and transactivates the matrilysin
promoter. Our results demonstrate that ERK–MAP
kinase and transcription factor STAT3 are important
components of FGF-1— mediated signaling, which
induce promatrilysin expression in LNCaP cells.
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Introduction
Prostate cancer is the leading male visceral cancer diag-
nosed and the second leading cause of cancer death in North
American men [1]. Even though extensive studies have been
pursued concerning prostate cancer, the cellular and
molecular mechanisms involved in the initiation and pro-
gression are not clear. Most prostate cancer–related deaths
are due to metastasis of the cancer cells to other tissues or
organs. Studies involving the mechanisms underlying the
metastasis, and the interactions between the prostate cancer
epithelial cells and their surrounding stromal cells, are
important in understanding the natural history of prostate
cancer. Prostate cancer has been associated with increased
matrix metalloproteinase (MMP) expression, which contrib-
utes to tumor cell invasion and metastasis [2 ]. Proteolysis of
the extracellular matrix proteins, which allows the migration of
neoplastic cells through the basal lamina into the interstitial
stroma, is an important event in the metastatic process of
prostate cancer. Also, the degradation of extracellular matrix
proteins helps in releasing the bound growth factors, such as
fibroblast growth factors (FGFs), which are capable of
influencing the function of neoplastic cells [3 ]. The MMPs,
a family of metal - requiring enzymes, are capable of degrad-
ing ECM proteins [4 ] and are found to be elevated in many
types of cancer including prostate cancer [5-7]. Matrilysin
(PUMP-1, MMP-7) is capable of degrading many extrac-
ellular matrix proteins, including proteoglycans, fibronectin,
entactin, laminin, gelatin, and elastin [8 ]. Matrilysin expres-
sion appears to predominate in epithelial cells of glandular
tissue, whereas other MMPs, like stromelysin and the
gelatinases, are more commonly expressed by cells in the
stromal compartment [8]. Matrilysin is overexpressed in
prostate cancer [7 ] and in inflamed ducts of the human
prostate, but is not expressed in normal prostate glands [9].
This overexpression could be due to stimulation by paracrine
factors from the surrounding stroma [10]. Previous reports
from our laboratory showed that, in the prostate carcinoma
cell line LNCaP, promatrilysin expression is enhanced by
factors secreted from prostate-derived fibroblasts, and this
enhancement is due to members of the FGF family [10].
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FGFs have been implicated in the development of numerous
malignancies including prostate cancer. There are at least 20
members of the FGF family, 10 of which have been
characterized in humans [11]; and expression of FGF-1,
FGF-2, FGF-7, FGF-9, and FGF-10 has been observed in
prostate stromal fibroblasts [10]. Because FGFs are present
in the prostate, a gain in sensitivity to FGF induction of
promatrilysin expression could have important consequen-
ces with regard to prostate cancer progression. There are
four different genes encoding high-affinity transmembrane
receptors, FGF receptors 1 to 4. FGFR-1 to FGFR-4 are
characterized by the presence of two or three immunoglo-
bulin- like domains in the extracellular region and a tyrosine
kinase domain in the intracellular region of the receptor [12].
These receptors are responsible for FGF-mediated signal
transduction. Further diversity in the FGF receptor family is
generated by alternative RNA splicing.
FGF receptor activation elicits phosphorylation of the
receptor and intracellular proteins, including phospholipase
C [13], and extracellular signal - regulated kinases (ERKs)
[14]. Mitogen-activated protein kinases (MAP kinase) are
serine–threonine kinases that are activated in response to
extracellular stimuli by a phosphorylation cascade involving
multiple kinases. ERKs belong to the MAP kinase family and
are one of the strong candidates in FGF-mediated signal
transduction. ERK1/2 is predominantly stimulated by mito-
gens and hormones inducing proliferation, cell growth, or
differentiation [15]. A number of transcription factors have
been identified as targets for MAP kinase. These tran-
scription factors enter the nucleus after phosphorylation by
MAP/ERK kinase [16]. Recently, it was shown that signal
transducer and activator of transcription 3 (STAT3) is a
substrate for MAP kinase [17].
Previous reports from our laboratory showed that, in
LNCaP cells, promatrilysin expression was mediated by
FGF-1 [10]. However, the signaling pathway leading to the
increase in promatrilysin expression is unknown. The goal of
this present study was to investigate the possible mecha-
nisms involved in FGF-1–mediated induction of promatrily-
sin expression in LNCaP cells. Our results show that the
ERK1/2–STAT3 pathway is activated by FGF-1, and that
blocking this pathway with a MAP kinase inhibitor abolishes
the induction of promatrilysin by FGF-1. These results
suggest that ERK1/2 and STAT3 may play roles as the
downstream mediators for the FGF-1–induced increase in
the promatrilysin expression in LNCaP cells.
Materials and Methods
Cell Culture and Reagents
LNCaP cells were obtained from the American Type
Culture Collection (Rockville, MD). LNCaP cell cultures were
maintained in Dulbecco’s modified Eagle medium (DMEM)
supplemented with 10% fetal bovine serum, 100 g/ml
penicillin, and 100 g/ml streptomycin, both from Gibco-
BRL (Rockville, MD). All cells were maintained in a
humidified incubator at 378C and 5% CO2. Recombinant
human FGFs were purchased from R&D Systems (Minne-
apolis, MN). MEK1/2 inhibitor PD98059, phospho-specific
antibodies, and general antibodies against ERK and STAT3
were obtained from New England Biolaboratories (Beverly,
MA). DMEM was obtained from Gibco-BRL (Gaithersburg,
MD). Fetal bovine serum was obtained from JRH Bioscien-
ces (Lenexa, KS).
Plasmid Constructs
The heterologous human matrilysin promoter (HMAT
luciferase) was generated using 1179 bp of the sequenced
human matrilysin promoter (GenBank accession no.
L22525) located directly upstream of the TATA box. This
sequence was amplified by polymerase chain reaction
(PCR) and subcloned into pTAL- luc (Promega, San Luis,
CA). PCR amplification of the matrilysin promoter (kindly
provided by the laboratory of Lynn Matrisian, Vanderbilt
University ) was carried out using the following heterologous
primers, which contained either NheI (upstream primer) or
XhoI (downstream primer) restriction site sequences linked
to matrilysin promoter-specific sequences (upstream pri-
mer 50 -CGTCTTGTCATTGGCGAATTC-30 and the down-
stream primer 50 -CCCCAGTGCAAGTGCAGGTGC-30 ).
The resultant 1217-bp amplification product was digested
with NheI /Xho, gel purified, and directionally cloned into
NheI /XhoI–digested pTAL- luc vector directly upstream of
the thymidine kinase minimal promoter. The resultant
plasmid construct was confirmed with DNA sequencing.
The pTAL- luc construct was used as a control plasmid. The
STAT3 dominant negative plasmid construct was provided
by the laboratory of Ralph A. Bradshaw (University of
California Medical School, Irvine, CA). The double mutant
STAT3 contains both Tyr - to-Phe and Ser- to-Ala muta-
tions preventing phosphorlylation at sites critical for STAT3
activity [18]. The parent vector (pCMV-1) into which the
STAT3 double mutant was cloned was used as a control
plasmid.
Transient Transfection and Reporter Gene Assays
LNCaP cells were grown to log phase by splitting
24 hours before being trypsinized, counted, and plated for
the experiment at 4104 cells /cm2 of a six-well plate.
Cells, at approximately 60% confluence 24 hours later,
were transfected with a DNA/DOTAP mixture made up of
2 g/well DNA ( in 50 l /well of 20 mM HEPES, pH 7.3)
and 4 g/well sonicated DOTAP (1, 2-diacyl -3- trimethy-
lammonium-propane) from Avanti Polar Lipids (Birming-
ham, AL) ( in 50 l /well of 20 mM HEPES, pH 7.3),
preincubated together for 20 minutes before being mixed
with 2 ml /well of serum-free medium. Cells were rinsed
once in serum-free medium, incubated with the DNA/
DOTAP medium for 12 hours, and allowed to grow for an
additional 12 hours in complete medium. Then the cells
were treated with FGF-1 (10 ng/ml). The cells were
harvested between 2 and 24 hours after treatment with
100 l of Luciferase Cell Culture Lysis Reagent from
Promega (Madison, WI) (25 mM Tris phosphate, pH 7.8,
2 mM DTT, 2 mM 1,2-diaminocyclohexane-N,N,N 0,N 0 -
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tetra acetic acid, 10% glycerol, 1% Triton X-100) and protein
amounts were determined using a Bio-Rad (Hercules, CA)
DC Protein Assay kit. Whole cell lysates (30 g) were
assayed in 50 l of Promega’s Luciferase Assay Reagent
using 3-second delay and 15-second integration on a
Turner Designs (Sunnyvale, CA) TD-20/20 Luminometer.
ELISA Assay for Promatrilysin
An antibody sandwich assay described previously [10]
was used for detection and quantification of promatrilysin
protein in culture medium. The capture antibody (10D2, a
mouse monoclonal antibody produced in the laboratory of
Dr. Raymond Nagle using purified matrilysin from Dr. Mark
Navre; Syntex, Palo Alto, CA) is specific for human
promatrilysin. The mouse monoclonal antibody, 10D2, was
coated onto 96-well EIA plates (Costar, Cambridge, MA).
The detection antibodies include antibody Rb2, a rabbit
polyclonal antibody to human matrilysin [9 ], followed by a
horseradish peroxidase–conjugated goat antirabbit antibody
(Pierce, Rockford, IL) used to detect the bound Rb2.
Horseradish peroxidase activity was quantitated using a
hydrogen peroxide/o -phenyldiamine (Sigma, St. Louis,
MO) colorimetric system. Purified promatrilysin (Syntex)
was used to generate a standard curve for each assay. The
assay was linear in the range of 0.2 to 12.5 ng/ml. Samples
were diluted prior to analysis until the readings fell within the
linear range of the assay and the results were multiplied by
the dilution factor.
Western Blot Analysis to Determine the Change in
Phosphorlylation Status of ERK1/2 and STAT3 Proteins
Detection of ERK1/2 and STAT3 proteins in the cells by
Western analysis was carried out with total and phospho-
specific anti -ERK1/2 and STAT3 antibody. The LNCaP cells
were pretreated with 20 M MAP kinase kinase inhibitor
(PD98059; Alexis, San Diego, CA) followed by FGF-1
treatment. Cells were harvested and total cellular protein
was extracted after 4, 12, 24, and 48 hours. Protein
determination was performed on the cell extracts using
DC protein assay kit (Bio-Rad) and 40 g of total protein
was loaded and separated on a 12% SDS polyacrylamide
gel by electrophoresis. Proteins were then transferred to a
polyvinylidene difluoride membrane (Millipore Immobilin P,
Bedford, MA) by electroblotting at 50 V at 48C for 12 to
16 hours using a transfer buffer containing 25 mM Tris,
190 mM glycine, and 20% methanol. The membrane was
blocked in 5% nonfat milk in TBST (10 mM Tris, pH 8.0,
150 mM NaCl, and 0.05% Tween-20) at room temperature
for 1 hour. Phospho-specific anti -ERK1/2 and STAT3 were
used as the primary antibodies. They were diluted to 1:1000
in dry milk /TBST and the membranes were incubated for
1 hour at room temperature and then washed three times
with TBST. Horseradish peroxidase–conjugated goat anti-
rabbit IgG was used as the secondary antibody at a dilution
1:2000 in 5% dry milk /TBST. The membrane was incubated
for 1 hour and then washed three times with TBST.
Antigen–antibody complexes were visualized by treating
the membranes with Western blotting ECL detection reagent
(Amersham International, Little Chalfont, UK) and exposing
the blot to Kodak autoradiographic film.
Results
FGF-1–Induced Promatrilysin Expression in LNCaP Cells
is Time-Dependent
Previous studies from our laboratory showed that FGF-1
induces promatrilysin expression in LNCaP cells. It was also
shown that nearly all of the matrilysin protein present in the
culture was in the 28-kDa proenzyme form [10]. In the
present study, we demonstrated that the promatrilysin
induction in LNCaP cells was time-dependent. The cultured
LNCaP cells were treated with FGF-1 (10 ng/ml) containing
sodium heparin (2 g/ml) under serum-free conditions. The
culture medium and the cell lysates were collected at
different time points. Following FGF-1 treatment, proma-
trilysin expression in the conditioned medium and the total
cell lysate was measured by ELISA. FGF-1–treated LNCaP
cells showed a time-dependent increase in promatrilysin
expression in the conditioned media as well as the cell
lysates. After FGF-1 addition, promatrilysin did not start to
accumulate in the medium until 18 to 24 hours (Figure 1A ).
At 48 hours, there was a four- to five- fold increase in
Figure 1. FGF-1– induced promatrilysin expression in LNCaP cells. (A )
LNCaP cells ( 4104 cells / cm2 ) were treated with 10 ml of serum- free
DMEM (control ) or with FGF-1 (10 ng /ml ), with 2 g /ml sodium heparin for
different time periods. The conditioned media were collected after 4, 6, 12,
18, 24, and 48 hours of incubation and ELISA was performed with antibodies
specific to promatrilysin. (B ) Total cell lysates were collected after 2, 6, 12,
24, and 48 hours of incubation and ELISA was performed with antibodies
specific to matrilysin. Each bar represents the mean and standard deviation
of three independent experiments run in triplicate.
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promatrilysin in the medium compared to the basal level at
that time. In contrast, when intracellular promatrilysin was
measured, there was a significant increase in promatrilysin
as early as 6 hours after addition of FGF-1 (Figure 1B ).
Activation of ERK1/2 Induced by FGF-1 is Inhibited by
MEK1/2 Inhibitor (PD98059)
MAP kinases have established themselves as key
regulators of gene expression through their ability to
phosphorylate transcription factors and modulate their
activity. Because the MEK/ERK pathway has been reported
to be stimulated by growth factors [19,20], we investigated
whether FGF-1 can activate the MEK/ERK pathway. To
determine the effect of FGF-1 on ERK, cultures of LNCaP
cells were stimulated with recombinant FGF-1 (10 ng/ml) in
the presence of 2 g/ml sodium heparin. After stimulation,
the activation of ERKs was evaluated by monitoring changes
in the phosphorylation status of ERK1/2. A time course of
the immunoreactivity detected with the anti–phospho-
ERK1/2 antibody by Western blot analyses of the whole
cell extracts is shown in Figure 2. The antibody recognizes
the kinases only when phosphorylated on Thr-202 and Tyr-
204 residues in their regulatory sequence. FGF-1 stimulated
the phosphorylation of ERK1/2 in a time-dependent
manner. The activation of ERK1/2 was observed as early
as 4 hours, increasing at 6 and 12 hours, and the maximum
induction was observed at 24 hours. The phosphorylation
of ERK1/2 in the presence of FGF-1 was sustained up to
24 hours and the increase in ERK activation decreased to
undetectable levels by 48 hours (data not shown). There
was no effect of FGF-1 on the total level of ERK proteins
across the entire time course. To differentiate between the
possible signaling pathways involved in FGF-1–induced
promatrilysin expression, we used an inhibitor of MEK/ERK
activation. The PD98059 has been described as a specific
inhibitor of the ERK1/2-activating kinase, MEK1/2 [20,36].
A dose–response study was carried out for PD98059 [10,
20, and 50 M (data not shown) ] and 20 M concentration
did not alter the cell number and the basal expression of
promatrilysin (data not shown), and this concentration of
PD98059 was used in further experiments. LNCaP cells
were pretreated for 1 hour with the MAP kinase kinase
inhibitor, PD98059 (20 M), prior to the addition of 10 ng/ml
FGF-1 in the presence of 2 g/ml sodium heparin. At
various times after treatment, cellular protein was isolated
from cells. The phosphorylated forms of ERK1/2 were
analyzed byWestern blotting with an antibody specific for the
activated forms of ERK1/2. Pretreatment with the MEK1/2
inhibitor, PD98059 (20 M), strongly inhibited the FGF-1–
induced activation of ERK1/2 at all time points studied
(Figure 2 ).
MEK1/2 Inhibitor (PD98059) Completely Abrogates
Promatrilysin Expression Induced by FGF-1
To further investigate the role of MAPKs in FGF-1–
induced promatrilysin expression, and to determine
whether the MEK1/2 inhibitor (PD98059) can inhibit the
expression of promatrilysin induced by FGF-1, cultures of
LNCaP cells were treated concurrently with PD98059 and
recombinant FGF-1 (10 ng/ml) in the presence of 2 g/ml
sodium heparin. LNCaP cells were pretreated with PD98059
(20 M) for 1 hour prior to FGF-1 treatment. The cells were
then treated with FGF-1 for different time periods (4, 12, 24,
and 48 hours). The media were collected and promatrilysin
expression was measured by ELISA. Pretreatment with the
MEK1/2 inhibitor completely abrogated the FGF-1–induced
promatrilysin expression in LNCaP cells indicating that the
FGF-1–induced promatrilysin expression requires the
ERK1/2 signaling pathway (Figure 3 ).
Transcription Enhancer Elements Present in the Matrilysin
Promoter Region are Responsive to FGF-1 and the
Induction was Blocked by PD98059
To determine if transcriptional activation of the matrilysin
gene promoter is involved in the FGF-1–induced increase in
steady state levels of matrilysin mRNA (data not shown), we
cloned a plasmid construct encoding the 1.2-kb human
Figure 2. FGF-1– induced activation of ERK1 /2 was inhibited by MEK1 /2
inhibitor PD98059 in LNCaP cells. MEK1 /2 inhibitor PD98059 inhibited FGF -
1– induced ERK activation. The LNCaP cells ( 4104 cells / cm2 ) were
pretreated with MEK1 / 2 inhibitor PD98059 (20 M) for 1 hour in serum- free
DMEM. After 1 hour, the cells were treated with 2 ml of serum- free DMEM
(control ) or with FGF -1 (10 ng /ml ), with 2 g /ml sodium heparin for different
time periods. Western analyses were performed with phospho -specific ERK
antibody for determining the inhibitory effect of PD98059 on FGF -1– induced
ERK activation. Whole cell lysates (40 g ) from control and FGF-1– treated
groups obtained from 4, 12, and 24 hours were analyzed. The results are
representative of three independent experiments.
Figure 3. FGF-1– induced promatrilysin expression in LNCaP cells was
inhibited by MEK1 /2 inhibitor PD98059. MEK1 /2 inhibitor PD98059 inhibited
FGF-1– induced promatrilysin expression. LNCaP cells ( 4104 cells / cm2 )
were pretreated with MEK1 / 2 inhibitor PD98059 (20 M) for 1 hour in serum-
free DMEM. After 1 hour, the cells were treated with 2ml of serum- free DMEM
(control ) or with FGF -1 (10 ng /ml ), with 2 g /ml sodium heparin for different
time periods ( 4, 12, 24, and 48 hours ). The conditioned media were collected
after 4, 12, 24, and 48 hours of incubation and ELISA was performed with
antibodies specific to promatrilysin. Each bar represents mean and standard
deviation of three independent experiments run in triplicate.
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matrilysin promoter driving a luciferase reporter gene. The
1.2-kb published human matrilysin promoter contains cis
elements that include a TPA response element (TRE), cyclic
AMP response element (CRE), serum response element
(SRE), and an interferon stimulatory response element
( ISRE). Apart from these cis elements, the human matrilysin
promoter sequence has a number of NF IL-6 elements to
which STAT3 may be capable of binding. We conducted
transient transfection experiments in LNCaP cells with this
1.2-kb human matrilysin promoter–TK–luciferase reporter
construct (HMAT-LUC). Treatment of HMAT-LUC–trans-
fected cells with 10 ng/ml FGF-1 in the presence of 2 g/ml
sodium heparin for 6 hours resulted in a four - to five- fold
increase in luciferase enzyme activity compared with
untreated controls (Figure 4 ), whereas no induction was
seen in cells transfected with the parental vector (pTAL- luc).
The induction of 1.2-kb matrilysin promoter by FGF-1 was
inhibited by the MEK1/2 inhibitor (PD98059) at all time
periods studied. The four- to five- fold increase in the
reporter gene was similar to the increase in promatrilysin
protein levels measured by ELISA.
The MEK1/2 Inhibitor, PD98059, Completely Inhibits
STAT3 Activation Induced by FGF-1
Recent reports have suggested that STAT3 is a
substrate of ERK–MAP kinases that phosphorylate STAT3
at serine 727. Serine phosphorylation of STAT3 may affect
both the nuclear translocation and DNA binding of the
transcription factor [21]. Therefore, we examined the ability
of FGF-1 to activate STAT3 in LNCaP cells in the
presence of the MAP kinase kinase inhibitor, PD98059.
Whole cell lysates were analyzed from LNCaP cells that
were treated for different time periods with FGF-1 (10 ng/
ml) to analyze the time-dependent activation of STAT3.
LNCaP cells were harvested as described in the Materials
and Methods section and the total cellular protein was
examined for the presence of STAT3 activation by Western
blot analyses. Serum–deprived LNCaP cells were pre-
treated with 20 M PD98059 for 1 hour and then stimulated
with FGF-1 (10 ng/ml) in the presence of 2 g/ml sodium
heparin. Western blot analyses revealed that STAT3 was
phosphorylated on serine 727 to some extent in the basal
conditions but was markedly enhanced with the addition of
FGF-1. The phosphorylation of STAT3 was more potently
stimulated between 6 and 12 hours after treatment with
FGF-1, was decreased at 24 hours, and became undetect-
able at 48 hours (Figure 5 ). The ability of FGF-1 to induce
the phosphorylation of STAT3 was inhibited completely by
the MEK1/2 inhibitor PD98059 at all time periods studied.
Figure 4. PD98059 inhibited the FGF-1– induced transactivation of the
1.2 - kb matrilysin promoter in LNCaP cells. LNCaP cells ( 4104 cells / cm2 )
were transfected with a plasmid construct encoding 1.2 kb of the human
matrilysin promoter driving a luciferase reporter gene. Following a 24 -hour
transfection, the cells were pretreated with PD98059 for 1 hour and then with
FGF-1 ( 10 ng /ml ). The cells were harvested at different time points indicated
between 2 and 24 hours with 100 l Luciferase Cell Culture Lysis Reagent
from Promega. Proteins ( 30 g ) were assayed in 50 l of Promega’s
Luciferase Assay Reagent on a luminometer. Each treatment group
represents at least three wells per experiment, and at least three experiments
were performed for each figure. Representative graphs are shown with error
bars representing the replicates for a particular experiment.
Figure 5. FGF-1– induced activation of STAT3 was inhibited by MEK1 /2
inhibitor PD98059 in LNCaP cells. MEK-1 / 2 inhibitor PD98059 inhibited
FGF-1– induced STAT3 activation. The LNCaP cells ( 4104 cells / cm2 )
were pretreated with MEK1 /2 inhibitor PD98059 (20 M) for 1 hour in serum-
free DMEM. After 1 hour, the cells were treated with 2 ml of serum- free DMEM
(control ) or with FGF-1 ( 10 ng /ml ), with 2 g /ml sodium heparin for different
time periods. Western analyses were performed with total and phospho -
specific STAT3 antibodies for determining the inhibitory effect of PD98059 on
FGF-1– induced STAT3 activation. Cell lysates (40 g ) from control and
FGF-1– treated groups obtained from 2, 6, 12, and 24 hours were loaded
analyzed. The results are representative of three independent experiments.
Figure 6. A STAT3 dominant negative mutant construct inhibits FGF -1–
induced transactivation from the 1.2 - kb human matrilysin promoter in LNCaP
cells. LNCaP cells ( 4104 cells / cm2 ) were transiently cotransfected with
HMAT -LUC and dominant negative STAT3 or HMAT-LUC and parent vector
( pCMV-1 ), the parent vector into which the dominant negative STAT3 was
cloned. Following a 24 -hour transfection, the cells were treated with FGF-1
( 10 ng /ml ). The cells were harvested at different time points between 2 and
24 hours ( here we show the 6 -hour time point ) with 100 l of Luciferase Cell
Culture Lysis Reagent from Promega. Total protein ( 30 g ) was assayed in
50 l of Promega’s Luciferase Assay Reagent on a luminometer. Each
treatment group represents at least three wells per experiment, and at least
three experiments were performed. Representative graphs are shown with
error bars representing the replicates for a particular experiment.
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A Dominant Negative STAT3 Inhibits FGF-1–Induced
Transactivation of the 1.2-kb Promoter
We then determined whether the FGF-1–induced activity
of the 1.2-kb human matrilysin promoter could be inhibited
by a STAT3 dominant negative construct. A dominant
negative double mutant STAT3 construct with mutations in
the Tyr and Ser phosphorylation sites, which prevent
phosphorylation both at tyrosine and serine that are critical
for STAT3 activation, has been used in this study. The parent
vector (pCMV-1) into which the STAT3 double mutant was
cloned was used as a control plasmid. After transient
cotransfections with the 1.2-kb human matrilysin reporter
and the STAT3 dominant negative or parent vector with
equimolar amounts, FGF-1–induced transactivation of the
1.2-kb human matrilysin promoter was measured. Expres-
sion of dominant negative STAT3 inhibited the FGF-1–
induced transactivation of the human matrilysin 1.2-kb
promoter (Figure 6 ).
Discussion
Matrilysin is known to play a role in prostate cancer
progression and metastasis [8 ]. It was shown earlier that
prostate cancer cells overexpress matrilysin [7,22]. Previ-
ously, we reported that stromally expressed FGF proteins
induce promatrilysin expression in prostate cancer cell line;
this finding may provide a mechanism for overexpression of
matrilysin observed in prostate cancer [10]. FGF proteins
have been shown to induce MMP expression in several
mesenchymal [23–25] and cancer cell types [26-28] but
not in normal prostate epithelial cells. Earlier, we have shown
that normal prostate epithelial cells do not express FGFR-1
receptor and forced expression of FGFR-1 made them
susceptible to FGF-mediated induction of promatrilysin
expression [29]. In a recent study from our laboratory, we
have shown that STAT3 plays a role downstream of IL-6 in
IL-1–induced promatrilysin expression in LNCaP cells
[41].
In this study, we provided evidence for the mechanism
involved in the signal transduction from FGF-1 to induced
expression of promatrilysin in LNCaP cells. It was shown
earlier from our laboratory that recombinant FGFs are
capable of inducing promatrilysin expression in the
prostate carcinoma cell line LNCaP [10] and FGF-1 was
effective at a much lower dose level than other FGF
proteins. FGF-1 was effective because of its high affinity
towards all the four known FGF receptors [30]. The
biological activities of the FGFs are initiated by binding to
cell surface receptors. The FGF receptors are encoded by
four genes, FGFR-1 to FGFR-4. The FGF receptors are
receptor tyrosine kinases composed of three immunoglo-
bulin- like extracellular domains, a transmembrane region,
and a cytoplasmic domain that is autophosphorylated upon
ligand binding [31]. Multiple alternative mRNA splicing
events further contribute to the diversity in the FGF
receptor family [32].
The data presented in this paper showed that FGF-1
induced promatrilysin expression in a time-dependent
manner in LNCaP cells. We observed that the promatrilysin
protein levels had accumulated by 24 and 48 hours with a
four- to five- fold increase. In our experiments, it was found
that the promatrilysin protein secreted into the medium is
delayed compared to the intracellular levels, and the
increase in the intracellular levels of promatrilysin protein
was observed as early as 6 hours, indicating that the
promatrilysin accumulates intracellularly before being
secreted into the medium after treatment. Delayed secretion
of proteins by LNCaP cells has been reported earlier [44]. It
has been shown by densitometric analysis that laminin
secretion was delayed in LNCaP cells compared to DU145
cells. Previously published data suggest that the lack of
oligomerization has been found to be a cause of retention of
many proteins in the rough endoplasmic reticulum [45,46],
which would explain the present findings with LNCaP cells.
To determine the signaling pathways involved in the
FGF-1–induced expression of promatrilysin, we investi-
gated the role of MAP kinases in the FGF-1–induced
promatrilysin expression. ERKs are coordinately activated in
response to a wide range of mitogenic and nonmitogenic
stimuli including the FGFs [14]. It was also shown that FGF
receptor activation causes tyrosine phosphorylation of the
receptor itself, and activation of extracellular regulated
kinases (ERKs). In retinal -pigmented epithelial cells, it
was observed that ERKs undergo rapid activation in
response to FGF-1 and FGF-2 [33]. Our results demon-
strate that ERK–MAP kinases play a major role in mediating
the FGF-1–induced promatrilysin expression in LNCaP
cells. Two pathways are known to transduce FGF-1 signals
generated by FGFR-1 stimulation — one dependent on
Ras and the other dependent on PLC [34,35]. Raf -1
integrates signals from these two pathways to activate the
MAP kinase cascade and MAPKs are important upstream
regulators of transcription factor activities.
Previously published reports suggest that transient
activation of cell surface receptors and subsequent activa-
tion of MAP kinase cascade contribute to the transcriptional
upregulation of MMPs. Activation of the ERK1/2 or the p38
MAP kinase pathway is sufficient to induce transcription from
theMMP-1 promoter in human primary fibroblasts [47]. Wan
et al. [48] have shown that in human keratinocytes, IL-1 –
induced expression of MMP-1 is mediated by activation of
EGF receptor and through ERK–MAP kinase pathway. It
was also demonstrated that P38 MAPK and ERK pathways
contribute to the transcriptional regulation of MMP-9 in
arterial smooth muscle cells [49]. Collectively, the literature
suggests that growth factors and cytokines are capable of
inducing MMPs through MAP kinase pathways, which
corroborates with our present data.
Further, we determined whether the FGF-1–induced
promatrilysin expression in LNCaP cells was mediated
through transcription. In this study, we were able to show
the transactivation of the matrilysin promoter by FGF-1 in
prostate cancer cell line LNCaP. FGF-1–mediated trans-
activation was demonstrated using a 1.2-kb human matri-
lysin promoter that was cloned into a pTAL- luc expression
vector. Transient transfections studies demonstrated that
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this matrilysin promoter was inducible by FGF-1 in LNCaP
cells. We observed a four- to five- fold increase with this
reporter gene, which was comparable to the FGF-1–
induced matrilysin protein levels. The 1.2-kb region of the
human matrilysin promoter, for which published sequence is
available, contains a number of cis elements that are known
to bind STAT3. These include multiple NF IL-6 binding
elements and one IRF binding element. Further investigation
showed that inhibiting the ERK pathway with a MEK1/2
inhibitor (PD98059) almost completely blocked FGF-1–
induced transactivation of the 1.2-kb human matrilysin
promoter. These data suggested that ERK pathway is
required for the FGF-1–induced transactivation of the
1.2-kb human matrilysin promoter.
Biochemical studies have shown that ERKs can phos-
phorylate a large number of proteins including transcription
factors, protein kinases, and cytosolic enzymes [37,38]. A
potential substrate for MAP kinase, belonging to a distinct
family of transcription factors, is signal transducers and
activators of transcription 3 (STAT3) [39]. We provided
evidence that ERK–MAP kinases are responsible for the
phosphorylation of STAT3 serine 727 in vitro in LNCaP cells
when induced with FGF-1. Treatment of the cells with the
MEK1/2 inhibitor, PD98059, resulted in a decrease in the
phosphorylation of STAT3 induced by FGF-1. Our data
suggest that, the FGF-1 signal transduction pathway leading
to induced promatrilysin expression involves ERK-depend-
ent pathways to phosphorylate Ser-727 on STAT3. It has
been shown early that basic FGF activates ERK1, ERK2,
and STAT3 in myoblast cells [42]. The authors demon-
strated that bFGF stimulation of myoblasts leads to a rapid
tyrosine phosphorylation of STAT3. Recent studies show
that ERKs, but not p38 or JNK, participate in STAT3 serine
phosphorylation in growth factor–stimulated cells [22].
STAT1, STAT3, and STAT4 have conserved MAP kinase
phosphorylation sites [39,40]. Though STAT1 has a con-
servedMAP kinase phosphorylation site, ERK–MAP kinases
have been shown to poorly activate STAT1. The authors also
reported that the difference in the activation of STATs is
due the difference in the amino acid sequence surrounding
the MAP kinase phosphorylation site of STAT1 and STAT3.
The mechanism by which the serine phosphorylation
influences the transcriptional activity is still unclear [43].
Chung et al. [21] have reported that both serine and
tyrosine phosphorylation of STAT3 are induced in cytokine
and growth factor signaling pathways. The predominant site
of serine phosphorylation and activation of STAT3 is on
serine 727. Using an antibody specific for STAT3 serine 727
phosphorylation, we showed that FGF-1 induces phosphor-
ylation of this site in an ERK-dependent manner in LNCaP
cells. In addition, we showed with a dominant negative
double mutant STAT3 construct with mutations in Tyr (705)
and Ser (727) that STAT3 activation is required for FGF-1–
induced transactivation of the matrilysin promoter.
We have provided evidence in our proposed model
(Figure 7 ) that ERK1/2 and STAT3 are involved in FGF-
1–mediated promatrilysin expression. FGF-1 binds to FGF
receptor and activates ERK1/2, which in turn activates
STAT3. The transcription factor STAT3 translocates to the
nucleus and binds specific cis elements in the 1.2-kb human
matrilysin promoter and stimulates transcription of the
matrilysin gene in LNCaP cells.
In conclusion, we have determined that FGF-1 induces
promatrilysin expression in LNCaP cells in a time-dependent
manner that involves ERK and STAT3. TheMEK1/2 inhibitor
(PD98059) blocked promatrilysin expression at the tran-
scriptional level. Though basic FGF has been shown earlier
to activate ERK and phosphorylate STAT3 (Tyr-705) in
myoblasts [43], this is the first report to show that acidic FGF
and STAT3 (Ser-727) are involved in the signaling leading
to the expression of a MMP. Our findings support the idea
that paracrine factors play an important role in the regulation
of matrilysin in human prostate cancer cells.
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